Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Conditions: Chronic Kidney Disease With High Proteinuria Interventions: Drug: Zibotentan/Dapagliflozin; Drug: Dapagliflozin Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Chronic Kidney Disease | Dapagliflozin | Forxiga | Proteinuria | Research | Study | Urology & Nephrology